Cancer clinical trials cooperative groups are in jeopardy, and changes are needed to enable the system to survive, chairmen of the groups wrote in a paper submitted to NCI. White paper makes 25 recommendations, including changing system incentives, review process, group integration with centers and SPOREs, and inclusion in CaBIG. This 8-page issue includes full text of the white paper.
Also New AACR President Lynn Matrisian plans emphasis on enhancing communication.
Peter Jones begins term as AACR president-elect. New directors elected.
AACR honors Emil Frei III for pioneering work in childhood leukemia.
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Break Through Cancer’s Tyler Jacks: “We’ve created a new operating model for collaborative cancer research.”
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ
